Member Info for appletree1

Cuddles, the current price shown on the NASDAQ website is apparently not the NASDAQ share price. Under the Key Data field it still states that the exchange is ' Other OTC' . The quoted price seems to still be just the OTC price. The finalization of the NASDAQ listing is probably close now but I assume it will be preceded by a formal announcement like the TLSA listing was.

"13. Okyo Pharma (OKYO): 7p Target 20p

We stick with an unloved biotech for the next stock in the Top 20, much of which is based not only on the fundamental value behind a company, but also the acknowledgement that H2 2021 has been brutal as far as the small cap space has been concerned. We have been treated to delayed / overpriced IPOs, and stock margins being raised at the drop of a hat, something which quite understandably might have caused some to chance their arm in the wild west of crypto trading. For Okyo Pharma, 2022 looks to be a comeback year. It has been gestating its dry eye treatment, something which was well flagged in July with the tie up with Ora. It would appear that professional investors started appreciating what is to come from the early autumn, with the shares gapping up from 4p. Indeed, OK-101 is a wonderfully subtle and game changing treatment, able to bind to the surface of the eye, to target the inflammatory cells. One would assume that the reason that shares of Okyo are not much higher than they are is that investors have perhaps not taken the time to appreciate the advance that OKYO has made. Indeed, they have also not appreciated the recent announcements that not only has U.S. Patent issued for use of OK-101 to treat dry eye disease, but that OK-101 is to skip straight to Phase 2 human clinical trials in H2 next year. Given the size of the market, the breakthrough, and the strength of the IP, it can be said that genuine blockbuster drugs do not come much quicker, cheaper, or with greater application than the one that OKYO has under its wing."

Surescreen seems to be legit as the sole UK manufacturer to date. They admitted through press articles that they source some components from China and that one of those components is the swab. On the face of it Surescreen probably make the test strips themselves and forward to ODX to do some or all of the cassetting/ final assembly.

Smoke and Mirrors and manipulation of SP this week. We have now had over 70% algo trades today and most trades today were algo buys at the 22.90 live offer price but marked up as sells due to skewed live to book pricing. So the algos are not selling the stock down currently and the buy/ sell ratio is clearly high and much higher than it looks. I suspect that this is probably the buy zone ahead of the next up-cycle. Add to that the fact that we might garner interest in New Year portfolio adjustments and I think now is a good time to add some more, so am doing so.

The RNS says that the certificates are being dispatched today, so I would expect HL and the other brokers to receive them just after New Year and for them to be acknowledged as a line in our accounts a few days later with a statement of number of shares held but no value attributed. Then will come the wait for Ricca to list on ASX, start trading and the shares to be attributed valuations.

Mike, I could be wrong but I dont think the wall of 100 share trades are by a retail trader. They are marked as algo trades like over 50% of all trades yesterday and 66% of all trades today. Are not most of the algo trades set by hedge funds or potentially others acting to control the price for the insto buyers and sellers? .

Per month I think, but does anyone know where the 20 Million per month Medusa production capacity figure comes from and if it is reliable? I can see online the press releases last year in December where Medusa were talking of having spent 20 Million pounds for ramping up production of their antibody tests in a Wirral manufacturing facility, hoping to be able to make up to 50 Million antibody tests per month. Will they switch some or all of that capacity to the Meduflow? We haven't had any RNS about Medusa manufacturing it yet as far as I can see - just GAD and ABDX for now. Is there mention of Medusa manufacturing it in a presentation that I missed?

Not too bad Pumpky, but just highlights the fact that the placing flipper just makes a mere 7k profit, when they would likely have stood to make approaching 105k profit on that same holding when the SP actually takes off. That's the difference between very short term trading and long term trading/ investing...

The majority of desktop review applications went in before the 1 September 2021 deadline and at the time MHRA were estimating 2 weeks for the review and approval. 1 November is when the enforcement of the CTDA suspended UK sales of all Covid tests (except the few that that were exempted due to already being used by NHS (eg the Chinese Innova LFT tests). Hopefully the Gov will decide to throw resources at the MHRA to help get through the CTDA back-log and hopefully GDR's POC test will be expedited. Either way, for now EU sales are the main opportunity and hopefully news of contracts will come through soon.

The stock ticker for Bezant on the AQUIS market is 'BZT.GB.PL' (as Mr Triumph mentioned above) so you can see it on this London South East platform too under the BZT.GB.PL ticker. Take a look at the ADVFN platform too, since it gives live prices (not 15 minute delayed) for these stocks, shows both AQSE and LSE trades for a dual listed stock like this in one window and in this case correctly marked your trade as a buy not a sell.

The 1Million shares buy at 2.45pm is marked AQSE on ADVFN which normally means it was placed on the AQUIS market rather than the London Stock Exchange, which is why its not visible here or on the Google share price chart. It's the same pool of shares and will factor in the calculation of the LSE share price but because the AQUIS market is hidden from view of many investors it gives the MMs a bit more smoke and mirrors sway over the market. ADVFN is a useful platform. You can scrounge free info from it with a freebie account and there is free access for data on AQUIS shares.

Merry Christmas to you too and best wishes especially for a prosperous New Year to you and all investors on this board.

Practically only two flip sells totalling under 30k pounds so far all day is relatively minor and not significantly affecting the buy/ sell ratio which is heavily biassed to buys (assuming no as yet unreported delayed sells). Not convinced that we will see a big surge in sells later today or tomorrow, given that logically most of the Primary Bid buyers will have been holders that know that this stock is at/close to its cyclical low and likely to double or treble with a bit more patience. Flipping for a mere 12% is unlikely to appeal to many.

The buys and sells are guesses by an algorithm that just looks at which side of the mid-price between book (published/ official) bid and book offer a trade falls. Since the book bid and book offer are published at intervals whereas the live bid and offer price can move much more rapidly, there are often periods when the live mid price and book mid price deviate. When they deviate the algo will get the trade guess wrong. The MMS often will exploit this fact to confuse the market and disguise the true situation to give them an upperhand.

No spread now. Bid and offer are both 27p.

MCAP is currently about 70.5 Million GBP (and we are at least now blue, 3% up on the day despite the NASDAQ index being in the red). I suspect that we will drift side-ways for the time-being until the BOD start to re-engage properly with share-holders/ the market. The analyst target on NASDAQ is 7.75 USD but we wont be seeing anywhere near that until real improvements start being made.

Mine are HL too and HL don't deal direct for this stock but via HSBC and wont be allowing online dealing. The HL online dealing page says to phone 0117 980 9800 to telephone deal. I haven't yet tried it myself. (HL warned previously that it would take a few weeks after the October listing on NASDAQ before the shares are actually tradable).

Thanks Rockz. I will try phoning her. Regarding the de-list risk - IMHO it is vanishingly small at present. When I say we have plenty of head-room for a reverse stock split, that is to say we have 80-90 times NASDAQ'S minimum thresh-hold of 1.1 million shares at 1 dollar.

Any stocks de-listing from NASDAQ generally go back onto the OTC for trading, but that would impact value and corporate reputation. In the present case there shouldn't be any real risk of de-listing from NASDAQ when the MCAP has loads of head-room for a simple consolidation (called a reverse stock split in the US) if needed. The reverse stock split mechanism is commonly used to avoid NASDAQ de-listing. It would, of course, be infinitely better if the stock recovers without need to resort to that. Who do we communicate with to request better share-holder engagement?

Would clearly be good if GDR's long-standing European Distributor Sysmex have plenty of potential sizeable buyers lined up. Not clear to me why Tiger needs to tout the implausible line that our distributor Sysmex are looking at a buy-out of GDR while another twitter guy talks of even Pfizer potentially looking at a buy-out of GDR.